Clinical Trials Logo

Clinical Trial Summary

The aim of the proposed work is to conduct a randomized controlled trial (RCT) evaluation of a behavior change intervention designed to enhance fluid-intake adherence (compliance) among hemodialysis patients. Patient non-adherence (non-compliance) with fluid-intake restrictions is a highly pervasive problem in the hemodialysis population with substantial consequences in terms of increased patient morbidity and mortality. Given the prevalence and clinical importance of adherence among ESRD patients, the design and evaluation of interventions to improve patient adherence is critically important. Surprisingly, however, little such empirical work has been conducted in this area.

The proposed RCT involves testing the efficacy of a behaviorally based, group-administered, "behavioral self regulation" intervention designed to increase adherence to fluid intake restrictions among hemodialysis patients. This structured intervention is designed to be delivered by healthcare providers in a clinical setting to groups of 4-10 patients over seven, one-hour weekly sessions. This study will compare the effect of the structured intervention group with the effect of an educational and support group on fluid-intake adherence in a sample of approximately 200 fluid non-adherent center hemodialysis patients over a 26-week follow-up period. Both clinical (interdialysis session weight gain) and self-report indices of fluid-intake adherence will be examined. We believe that the proposed research is of potentially very high impact given the high prevalence and clear clinical consequences of hemodialysis patient nonadherence and the potential for a relatively low-cost, structured intervention to significantly reduce this type of maladaptive patient behavior in the hemodialysis treatment context.


Clinical Trial Description

Upon consent and enrollment into the study, patients will be given a packet of questionnaires to take home, complete, and return using a postage-paid envelope. These questionnaires will include a patient background form, which includes information on age, gender, marital status, years of education, employment status, and race/ethnicity, and two measure of health beliefs and attitudes (the Krantz Health Opinion Survey and the Multidimensional Health Locus of Control Scale. A copy of all measures in attached to this application.

Following consent and randomization participants will be assigned to one of two comparison study arms. Both study arms involve participation in a weekly, hour-long, patient support group for seven weeks. As described below the groups differ in terms of the content focus.

Patients randomly assigned to the Self-Regulation arm will meet in groups of 4-10 participants at their usual hemodialysis clinic for hour-long weekly sessions for seven weeks. Two to four groups will be conducted at each participating center depending on center size. Groups will be led by a member of the UIHC research team with at least two years previous professional experience with behavior change techniques, at least two years previous experience with the hemodialysis population, and a master's or doctoral level degree in psychology. Each UIHC team group leader will be responsible for 3-4 groups over the duration of the project. Session material utilized by group-leaders will be highly structured and detailed across the seven sessions. Self-Regulation group sessions will be generally highly leader-directed though participants will be regularly encouraged to share their experiences dealing with the dialysis regimen. A consistent attempt will be made to focus all group discussion on self-regulatory principles as they related to treatment adherence. An outline of topics for the Self-Regulation groups is attached.

Patients randomly assigned to the Support and Discussion arm will also meet in groups of 4-10 participants at their usual hemodialysis clinic for hour-long weekly sessions for seven weeks. Two to four groups will be conducted at each participating center depending on center size. These groups will be also led by a member of the UIHC research team, with each group leader responsible for 3-4 groups over the duration of the project. The Support and Discussion protocol will consist of two integrated components: (a) brief educational materials presented at the start of each session, and (b) group leader facilitated discussion following presentation of the educational materials. An outline of topics for the Support and Discussionn groups is also attached.

Patient adherence to the fluid-intake regimen will be determined by computing the amount of weight a patient gained between dialysis treatment sessions (termed "interdialytic weight gain" or IWG) as recorded in the patient's regular medical record. Mean IWG averaged over two weeks (six sessions) at each assessment point will serve as the primary dependent measure in this study. The pre-enrollment assessment (Time 0) will comprise the two weeks immediately preceding the start of group meetings, Time 1 will comprise the two weeks immediately following the final intervention session, Time 2 will comprise the 12th and 13th post-intervention weeks and the Time 3 assessment will consist of the 25th and 26th post-intervention weeks. Patients will also be asked to complete a previously validated self-report assessment of hemodialysis patient adherence to fluid restrictions (Dialysis Diet and Fluid Non-Adherence Questionnaire). This measure assesses fluid-intake adherence over the previous two weeks and will be obtained on a schedule which parallels the collection of the clinical IWG data. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Supportive Care


Related Conditions & MeSH terms


NCT number NCT01066949
Study type Interventional
Source University of Iowa
Contact
Status Completed
Phase Phase 2
Start date June 2006
Completion date June 2011

See also
  Status Clinical Trial Phase
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Terminated NCT04043026 - The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
Completed NCT05318014 - Low-protein Formula Supplements in Chronic Kidney Disease N/A
Active, not recruiting NCT06071065 - Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients N/A
Completed NCT02878317 - Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
Not yet recruiting NCT06039254 - Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function Phase 1
Recruiting NCT03160326 - The QUALITY Vets Project: Muscle Quality and Kidney Disease
Completed NCT02836574 - A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease Phase 2
Withdrawn NCT02885545 - The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial Phase 4
Completed NCT02896309 - The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity N/A
Completed NCT02756520 - Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
Completed NCT02875886 - DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease Phase 4
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Active, not recruiting NCT02483039 - Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization N/A
Completed NCT02369549 - Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease Phase 3
Terminated NCT02543177 - Optimised Procedure in Patients With NSTEMI and CKD N/A
Completed NCT02992548 - Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease Phase 4
Recruiting NCT02205944 - Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes N/A
Active, not recruiting NCT02231138 - Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Phase 4